.Attributes Medicine, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) therapy of people with HER2+ innovative bosom cancer cells as well as active or steady mind metastases presented consistent intracranial task and also wide spread effectiveness of T-DXd.